Search

Your search keyword '"Naomoto, Yoshio"' showing total 200 results
Start Over Author "Naomoto, Yoshio" Search Limiters Peer Reviewed
200 results on '"Naomoto, Yoshio"'

6. Circulating cell-free DNA methylation patterns as non-invasive biomarkers to monitor colorectal cancer treatment efficacy without referencing primary site mutation profiles.

Author

Yasui, Kazuya, Toshima, Toshiaki, Inada, Ryo, Umeda, Yuzo, Yano, Shuya, Tanioka, Hiroaki, Nyuya, Akihiro, Fujiwara, Toshiyoshi, Yamada, Takeshi, Naomoto, Yoshio, Goel, Ajay, and Nagasaka, Takeshi

Subjects
CIRCULATING tumor DNA, DNA methylation, COLORECTAL cancer, TREATMENT effectiveness, CANCER treatment, BIOMARKERS
Abstract

This study investigates methylation patterns in circulating cell-free DNA (ccfDNA) for their potential role in colorectal cancer (CRC) detection and the monitoring of treatment response. Through methylation microarrays and quantitative PCR assays, we analyzed 440 samples from The Cancer Genome Atlas (TCGA) and an additional 949 CRC samples. We detected partial or extensive methylation in over 85% of cases within three biomarkers: EFEMP1, SFRP2, and UNC5C. A methylation score for at least one of the six candidate regions within these genes' promoters was present in over 95% of CRC cases, suggesting a viable detection method. In evaluating ccfDNA from 97 CRC patients and 62 control subjects, a difference in methylation and recovery signatures was observed. The combined score, integrating both methylation and recovery metrics, showed high diagnostic accuracy, evidenced by an area under the ROC curve of 0.90 (95% CI = 0.86 to 0.94). While correlating with tumor burden, this score gave early insight into disease progression in a small patient cohort. Our results suggest that DNA methylation in ccfDNA could serve as a sensitive biomarker for CRC, offering a less invasive and potentially more cost-effective approach to augment existing cancer detection and monitoring modalities, possibly supporting comprehensive genetic mutation profiling. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Decreased risk of esophageal cancer owing to cigarette and alcohol cessation in smokers and drinkers: a systematic review and meta-analysis

Author

Miyazaki, Tatsuya, Kitagawa, Yuko, Kuwano, Hiroyuki, Kusano, Motoyasu, Oyama, Tuneo, Muto, Manabu, Kato, Hiroyuki, Takeuchi, Hiroya, Toh, Yasushi, Doki, Yuichiro, Naomoto, Yoshio, Nemoto, Kenji, Matsubara, Hisahiro, Yanagisawa, Akio, Uno, Takashi, Kato, Ken, Yoshida, Masahiro, Kawakubo, Hirofumi, Booka, Eisuke, Kawamura, Osamu, Fukuchi, Minoru, Sakai, Makoto, Sohda, Makoto, Nakajima, Masanobu, and The Committee for the “Guidelines for diagnosis and treatment of carcinoma of the esophagus” of the Japan Esophageal Society

Published
2017
Full Text
View/download PDF

10. Neo-adjuvant therapy or definitive chemoradiotherapy can improve laryngeal preservation rates in patients with cervical esophageal cancer. A Japanese nationwide survey

Author

Kato, Hiroyuki, Kitagawa, Yuko, Kuwano, Hiroyuki, Toh, Yasushi, Kusano, Motoyasu, Oyama, Tuneo, Muto, Manabu, Takeuchi, Hiroya, Doki, Yuichiro, Naomoto, Yoshio, Nemoto, Kenji, Matsubara, Hisahiro, Miyazaki, Tatsuya, Yanagisawa, Akio, Uno, Takashi, Kato, Ken, Yoshida, Masahiro, Kawakubo, Hirofumi, Booka, Eisuke, Nakajima, Masanobu, Kaneko, Koichi, Shiotani, Akihiro, and The Committee for the “Guidelines for diagnosis and treatment of carcinoma of the esophagus” in the Japan Esophageal Society

Published
2016
Full Text
View/download PDF

11. A nation-wide survey of follow-up strategies for esophageal cancer patients after a curative esophagectomy or a complete response by definitive chemoradiotherapy in Japan

Author

Toh, Yasushi, Kitagawa, Yuko, Kuwano, Hiroyuki, Kusano, Motoyasu, Oyama, Tsuneo, Muto, Manabu, Kato, Hiroyuki, Takeuchi, Hiroya, Doki, Yuichiro, Naomoto, Yoshio, Nemoto, Kenji, Matsubara, Hisahiro, Miyazaki, Tatsuya, Yanagisawa, Akio, Uno, Takashi, Kato, Ken, Yoshida, Masahiro, Kawakubo, Hirofumi, and Booka, Eisuke

Published
2016
Full Text
View/download PDF

14. Genomic and Epigenetic Alterations Deregulate microRNA Expression in Human Epithelial Ovarian Cancer

Author

Zhang, Lin, Volinia, Stefano, Bonome, Tomas, Calin, George Adrian, Greshock, Joel, Yang, Nuo, Liu, Chang-Gong, Giannakakis, Antonis, Alexiou, Pangiotis, Hasegawa, Kosei, Johnstone, Cameron N., Megraw, Molly S., Adams, Sarah, Lassus, Heini, Huang, Jia, Kaur, Sippy, Liang, Shun, Sethupathy, Praveen, Leminen, Arto, Simossis, Victor A., Sandaltzopoulos, Raphael, Naomoto, Yoshio, Katsaros, Dionyssios, Gimotty, Phyllis A., DeMichele, Angela, Huang, Qihong, Bützow, Ralf, Rustgi, Anil K., Weber, Barbara L., Birrer, Michael J., Hatzigeorgiou, Artemis G., Croce, Carlo M., and Coukos, George

Published
2008
Full Text
View/download PDF

15. Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib.

Author

Katsumata, Ryo, Monobe, Yasumasa, Katata, Yosuke, Fujiwara, Hideyo, Urano, Takashi, Akagi, Akihisa, Tsujimoto, Kotone, Konishi, Takako, Manabe, Noriaki, Kamada, Tomoari, Kawamoto, Hirofumi, Yamatsuji, Tomoki, and Naomoto, Yoshio

Subjects
GASTROINTESTINAL stromal tumors, IMATINIB, PROTEIN-tyrosine kinase inhibitors, RECTUM tumors, SUNITINIB
Abstract

Tyrosine kinase inhibitors (TKIs) such as imatinib improve the prognosis of patients with gastrointestinal stromal tumors (GISTs). However, treatment options for GISTs are still limited, and the continuation of TKIs is difficult due to adverse events in some cases. The effectiveness of low-dose imatinib is unclear. We report 2 cases to show effectiveness of low-dose imatinib in patients with adverse events. The first case is a male in his early 60s with a history of intestinal GIST resection who was diagnosed with recurrent GIST with peritoneal dissemination. He was started on low-dose imatinib (300 mg) because of a history of subconjunctival hemorrhage after receiving postoperative imatinib. Follow-up contrast-enhanced ultrasonography revealed that the tumors had shrunk in size and number after 2 months of treatment with 300-mg imatinib. He continued this treatment and showed partial response for 8 months. The second case is a female in her late 70s with rectal GIST who was treated with imatinib 400 mg. Due to a severe skin lesion, she changed her treatment to sunitinib 2 months after initiation. However, new metastasis in the liver was confirmed after 4 months of administration of sunitinib. She underwent surgical esection of the rectal tumor to reduce the volume. After the surgery, low-dose imatinib (300 mg) with oral steroids was adopted. Follow-up confirmed the absence of recurrence at the rectum and no increase in hepatic tumor size for 18 months. Aggressive treatment with low-dose imatinib instead of discontinuation or alteration of treatment may benefit patients with unresectable and postoperative GISTs with sensible mutation to imatinib. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

20. and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung

Author

Maeda, Yutaka, Tsuchiya, Tomoshi, Hao, Haiping, Tompkins, David H., Xu, Yan, Mucenski, Michael L., Du, Lingling, Keiser, Angela R., Fukazawa, Takuya, Naomoto, Yoshio, Nagayasu, Takeshi, and Whitsett, Jeffrey A.

Subjects
Gene expression -- Research, Haplotypes -- Identification and classification, Adenocarcinoma -- Diagnosis -- Care and treatment, Lung cancer -- Diagnosis -- Care and treatment, Health care industry
Abstract

Mucinous adenocarcinoma of the lung is a subtype of highly invasive pulmonary tumors and is associated with decreased or absent expression of the transcription factor NK2 homeobox 1 (NKX2-1; also known as TTF-1). Here, we show that haploinsufficiency of Nkx2-1 in combination with oncogenic [Kras.sup.G12D], but not with oncogenic [EGFR.sup.L858R], caused pulmonary tumors in transgenic mice that were phenotypically similar to human mucinous adenocarcinomas. Gene expression patterns distinguished tumor goblet (mucous) cells from nontumorigenic airway and intestinal goblet cells. Expression of NKX2-1 inhibited urethane and oncogenic [Kras.sup.G12D]-induced tumorigenesis in vivo. Haploinsufficiency of Nkx2-1 enhanced [Kras.sup.G12D]-mediated tumor progression, but reduced [EGFR.sup.L858R]-mediated progression. Genome-wide analysis of gene expression demonstrated that a set of genes induced in mucinous tumors was shared with genes induced in a nontumorigenic chronic lung disease, while a distinct subset of genes was specific to mucinous tumors. ChIP with massively parallel DNA sequencing identified a direct association of NKX2-1 with the genes induced in mucinous tumors. NKX2-1 associated with the AP-1 binding element as well as the canonical NKX2-1 binding element. NKX2-1 inhibited both AP-1 activity and tumor colony formation in vitro. These data demonstrate that NKX2-1 functions in a context-dependent manner in lung tumorigenesis and inhibits [Kras.sup.G12D]-driven mucinous pulmonary adenocarcinoma., Introduction Mucinous adenocarcinoma of the lung (formerly known as mucinous bronchioalveolar cancer) is pathologically classified as tumor cells with goblet cell morphology containing abundant intracytoplasmic mucin (1). Invasive mucinous adenocarcinoma [...]

Published
2012
Full Text
View/download PDF

32. Helicobacter pylori-Negative Advanced Gastric Cancer Arising from the Gastric Mucosa without Inflammation, Atrophy, or Intestinal Metaplasia.

Author

Hayashi, Jiro, Yamatsuji, Tomoki, Suehiro, Mitsuhiko, Haruma, Ken, Katsumata, Ryo, Kawamoto, Hirofumi, Kamada, Tomoari, Yoshida, Kazuhiro, Yoneda, Masamichi, Monobe, Yasumasa, and Naomoto, Yoshio

Subjects
ATROPHIC gastritis, HELICOBACTER pylori infections, GASTRIC mucosa, STOMACH cancer, METAPLASIA, ATROPHY, HELICOBACTER pylori
Abstract

Gastric cancer is strongly associated with atrophic gastritis associated with Helicobacter pylori infection. The eradication of H. pylori has been reported to improve inflammation of the gastric mucosa, atrophy, and intestinal metaplasia and has also been shown to inhibit the development and growth of gastric cancer. Advanced gastric cancer from H. pylori-negative mucosa without inflammation, atrophy, or intestinal epithelialization is rarely found. We report on two cases of advanced gastric cancer without endoscopic evidence of gastric mucosal atrophy. One case was in the gastric angle 9 years after H. pylori eradication and the other case was in the pylorus of an uninfected stomach. Although gastric cancer is strongly associated with atrophic gastritis caused by H. pylori infection, postoperative histopathological examination of the stomach in both cases showed no inflammation, atrophy, or intestinal metaplasia. Poorly differentiated adenocarcinomas were confirmed at the microscopic level, and both cases were determined to be type 4 using the Borrmann classification. There is a body of evidence showing that H. pylori infection can cause gastric cancer and is the most prevalent infection-induced cancer in the world. The 2 cases here displayed different carcinogenesis than gastric mucosal atrophy caused by H. pylori infection. With the spread of H. pylori eradication treatments and an increasing number of uninfected patients, these case reports can contribute to future strategies for the diagnosis of gastric cancer. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

33. Neuroendocrine tumor secondary to pulmonary hypoplasia: A case report.

Author

Yukawa, Takuro, Ishida, Yuta, Naomoto, Yoshio, Monobe, Yasumasa, Fukazawa, Takuya, and Yamatsuji, Tomoki

Subjects
LUNG abnormalities, NEUROENDOCRINE tumors, PNEUMONECTOMY, DISEASE risk factors
Abstract

Pulmonary hypoplasia is diagnosed during the perinatal period and is a cause of death in newborns. However, these developmental abnormalities are diagnosed in adulthood in some cases. A 70‐year‐old male smoker was diagnosed with stage IIIA pulmonary adenocarcinoma in the right upper lobe with right middle lobe hypoplasia. He subsequently underwent right upper and middle lobectomy with lymph node dissection by video‐assisted thoracoscopic surgery. In addition to an invasive adenocarcinoma in the right upper lobe, pathological examination of the hypoplastic lobe revealed neuroendocrine hyperplasia, as well as tumorlets and a typical carcinoid. Eight cases of pulmonary neuroendocrine tumors that developed from pulmonary hypoplasia have been reported to date. Interestingly, all but one case occurred in the right middle lobe. Neuroendocrine cell hyperplasia has been reported to develop in hypoplastic lungs postnatally; therefore, we speculated that the lesion was the origin of these neuroendocrine tumors. Moreover, the pathological findings suggested that atelectasis was involved in the pathogenesis of this rare condition. In adults, when lobar hypoplasia is diagnosed, neuroendocrine tumors should be anticipated. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

35. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen

Author

Kakimi, Kazuhiro, Isobe, Midori, Uenaka, Akiko, Wada, Hisashi, Sato, Eiichi, Doki, Yuichiro, Nakajima, Jun, Seto, Yasuyuki, Yamatsuji, Tomoki, Naomoto, Yoshio, Shiraishi, Kenshiro, Takigawa, Nagio, Kiura, Katsuyuki, Tsuji, Kazuhide, Iwatsuki, Keiji, Oka, Mikio, Pan, Linda, Hoffman, Eric W., Old, Lloyd J., and Nakayama, Eiichi

Published
2011
Full Text
View/download PDF

40. Hypoxia activates the cyclooxygenase-2–prostaglandin E synthase axis

Author

Lee, James J., Natsuizaka, Mitsuteru, Ohashi, Shinya, Wong, Gabrielle S., Takaoka, Munenori, Michaylira, Carmen Z., Budo, Daniela, Tobias, John W., Kanai, Michiyuki, Shirakawa, Yasuhiro, Naomoto, Yoshio, Klein-Szanto, Andres J.P., Haase, Volker H., and Nakagawa, Hiroshi

Published
2010

48. Translocation of heparanase into nucleus results in cell differentiation

Author

Nobuhisa, Tetsuji, Naomoto, Yoshio, Okawa, Takaomi, Takaoka, Munenori, Gunduz, Mehmet, Motoki, Takayuki, Nagatsuka, Hitoshi, Tsujigiwa, Hidetsugu, Shirakawa, Yasuhiro, Yamatsuji, Tomoki, Haisa, Minoru, Matsuoka, Junji, Kurebayashi, Junichi, Nakajima, Motowo, Taniguchi, Shunʼichiro, Sagara, Junji, Dong, Jian, and Tanaka, Noriaki

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results